A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Latest Information Update: 17 Sep 2025
At a glance
- Drugs 4D-150 (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms PRISM
- Sponsors 4D Molecular Therapeutics
Most Recent Events
- 24 Jul 2025 According to a 4D Molecular Therapeutics media release, results from this trial will be presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, on August 1, 2025 (11:24 - 11:27 a.m. PT), by John A. Wells.
- 25 Jun 2025 Planned End Date changed from 1 Nov 2026 to 1 Jan 2031.
- 25 Jun 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2027.